Jane Visvader

Last updated

Jane Visvader
Jane Visvader.jpg
Alma mater University of Adelaide
Scientific career
Institutions Walter and Eliza Hall Institute of Medical Research
Salk Institute

Jane Visvader FRS FAA FAHMS is a scientist specialising in breast cancer research who works for the Walter and Eliza Hall Institute in Melbourne, Australia. She is the joint head of the Breast Cancer Laboratory with Geoff Lindeman. [1]

Contents

Education

Visvader holds a PhD in Biochemistry from the University of Adelaide having studied structure and function of citrus exocortis viroid [2]

Career and research

After her PhD [3] in the Department of Biochemistry at the University of Adelaide , she was a postdoctoral researcher with Inder Verma (Salk Institute, San Diego) and Jerry Adams (Walter and Eliza Hall Institute (WEHI)). [4] She worked at the Children's Hospital/Harvard Medical School in Boston before returning to Victoria in 1997 to establish a Breast Cancer Laboratory at WEHI. [4]

Visvader has published work investigating the role of cells of origin in cancer [5] and in particular focuses on the role of stem cells, [6] [7] which she believes may be a key to understanding breast cancer. [8]

Visvader is a board member of the Cancer Council Victoria, Medical & Scientific Committee. [9]

Patents

Visvader is a named inventor on five patents relating to cancer research focused on stem cell isolation and diagnostics. [10]

Awards and recognition

Selected publications

Related Research Articles

<span class="mw-page-title-main">Mammary gland</span> Exocrine gland in humans and other mammals

A mammary gland is an exocrine gland in humans and other mammals that produces milk to feed young offspring. Mammals get their name from the Latin word mamma, "breast". The mammary glands are arranged in organs such as the breasts in primates, the udder in ruminants, and the dugs of other animals. Lactorrhea, the occasional production of milk by the glands, can occur in any mammal, but in most mammals, lactation, the production of enough milk for nursing, occurs only in phenotypic females who have gestated in recent months or years. It is directed by hormonal guidance from sex steroids. In a few mammalian species, male lactation can occur. With humans, male lactation can occur only under specific circumstances.

Mouse mammary tumor virus (MMTV) is a milk-transmitted retrovirus like the HTL viruses, HI viruses, and BLV. It belongs to the genus Betaretrovirus. MMTV was formerly known as Bittner virus, and previously the "milk factor", referring to the extra-chromosomal vertical transmission of murine breast cancer by adoptive nursing, demonstrated in 1936, by John Joseph Bittner while working at the Jackson Laboratory in Bar Harbor, Maine. Bittner established the theory that a cancerous agent, or "milk factor", could be transmitted by cancerous mothers to young mice from a virus in their mother's milk. The majority of mammary tumors in mice are caused by mouse mammary tumor virus.

<span class="mw-page-title-main">WEHI</span> Medical research institute in Victoria, Australia

WEHI, previously known as the Walter and Eliza Hall Institute of Medical Research, and as the Walter and Eliza Hall Institute, is Australia's oldest medical research institute. Sir Frank Macfarlane Burnet, who won the Nobel Prize in 1960 for his work in immunology, was director from 1944 to 1965. Burnet developed the ideas of clonal selection and acquired immune tolerance. Later, Professor Donald Metcalf discovered and characterised colony-stimulating factors. As of 2015, the institute hosted more than 750 researchers who work to understand, prevent and treat diseases including blood, breast and ovarian cancers; inflammatory diseases (autoimmunity) such as rheumatoid arthritis, type 1 diabetes and coeliac disease; and infectious diseases such as malaria, HIV and hepatitis B and C.

<span class="mw-page-title-main">Amphiregulin</span> Protein-coding gene in the species Homo sapiens

Amphiregulin, also known as AREG, is a protein synthesized as a transmembrane glycoprotein with 252 aminoacids and it is encoded by the AREG gene. in humans.

<span class="mw-page-title-main">Cancer stem cell</span> Cancer cells with features of normal cells

Cancer stem cells (CSCs) are cancer cells that possess characteristics associated with normal stem cells, specifically the ability to give rise to all cell types found in a particular cancer sample. CSCs are therefore tumorigenic (tumor-forming), perhaps in contrast to other non-tumorigenic cancer cells. CSCs may generate tumors through the stem cell processes of self-renewal and differentiation into multiple cell types. Such cells are hypothesized to persist in tumors as a distinct population and cause relapse and metastasis by giving rise to new tumors. Therefore, development of specific therapies targeted at CSCs holds hope for improvement of survival and quality of life of cancer patients, especially for patients with metastatic disease.

<span class="mw-page-title-main">Richard Pestell</span> Australian oncologist and endocrinologist

Richard G. Pestell is an Australian American oncologist, endocrinologist and research scientist. Pestell was appointed an Officer of the Order of Australia for distinguished service to medicine and medical education in 2019 by Queen Elizabeth II. He was previously Executive Vice President of Thomas Jefferson University and Director of the Sidney Kimmel Cancer Center of Thomas Jefferson University. He founded six biotechnology companies developing cancer therapy and diagnostics. He is currently Distinguished Professor, Translational Medical Research, and the President of the Pennsylvania Cancer and Regenerative Medicine Research Center at the Baruch S. Blumberg Institute.

<span class="mw-page-title-main">CD24</span> Mammalian protein found in Homo sapiens

Signal transducer CD24 also known as cluster of differentiation 24 or heat stable antigen CD24 (HSA) is a protein that in humans is encoded by the CD24 gene. CD24 is a cell adhesion molecule.

<span class="mw-page-title-main">Transcription factor Jun</span> Mammalian protein found in Homo sapiens

Transcription factor Jun is a protein that in humans is encoded by the JUN gene. c-Jun, in combination with protein c-Fos, forms the AP-1 early response transcription factor. It was first identified as the Fos-binding protein p39 and only later rediscovered as the product of the JUN gene. c-jun was the first oncogenic transcription factor discovered. The proto-oncogene c-Jun is the cellular homolog of the viral oncoprotein v-jun. The viral homolog v-jun was discovered in avian sarcoma virus 17 and was named for ju-nana, the Japanese word for 17. The human JUN encodes a protein that is highly similar to the viral protein, which interacts directly with specific target DNA sequences to regulate gene expression. This gene is intronless and is mapped to 1p32-p31, a chromosomal region involved in both translocations and deletions in human malignancies.

<span class="mw-page-title-main">ERBB3</span> Protein found in humans

Receptor tyrosine-protein kinase erbB-3, also known as HER3, is a membrane bound protein that in humans is encoded by the ERBB3 gene.

<span class="mw-page-title-main">Cyclin-dependent kinase 7</span> Protein-coding gene in the species Homo sapiens

Cyclin-dependent kinase 7, or cell division protein kinase 7, is an enzyme that in humans is encoded by the CDK7 gene.

<span class="mw-page-title-main">RBBP8</span> Protein-coding gene in the species Homo sapiens

Retinoblastoma-binding protein 8 is a protein that in humans is encoded by the RBBP8 gene.

<span class="mw-page-title-main">TBX3</span> Protein-coding gene in the species Homo sapiens

T-box transcription factor TBX3 is a protein that in humans is encoded by the TBX3 gene.

<span class="mw-page-title-main">LMO4</span> Protein-coding gene in the species Homo sapiens

LIM domain transcription factor LMO4 is a protein that in humans is encoded by the LMO4 gene.

<span class="mw-page-title-main">STARD10</span> Protein-coding gene in the species Homo sapiens

StAR-related lipid transfer protein 10 (STARD10) or PCTP-like protein is a lipid transfer protein that in humans is encoded by the STARD10 gene. The protein derives its name from the fact that the molecule contains a START domain. As part of the StarD2 subfamily, StarD10 can transport the lipids phosphatidylcholine and phosphatidylethanolamine between membranes in solution. Casein kinase II phosphorylates the protein on its serine at position 184.

<span class="mw-page-title-main">Joan Massagué</span> Spanish biologist

Joan Massagué, is a Spanish biologist and the current director of the Sloan Kettering Institute at Memorial Sloan Kettering Cancer Center. He is also an internationally recognized leader in the study of both cancer metastasis and growth factors that regulate cell behavior, as well as a professor at the Weill Cornell Graduate School of Medical Sciences.

Barry Austin Gusterson is an Emeritus Professor of Pathology at the University of Glasgow. He was previously Professor of Pathology and Head of the Section of Molecular Pathology at the Institute of Cancer Research in London, and Founding Director of the Toby Robins Breakthrough Breast Cancer Research Centre. In 2000-2010 he was Professor of Pathology in Glasgow and was the project lead responsible for building the Wolfson Wohl Cancer Centre. He is known for his research on EGFR in head and neck cancer, and HER2 in breast cancer and breast development.

Breast cancer metastatic mouse models are experimental approaches in which mice are genetically manipulated to develop a mammary tumor leading to distant focal lesions of mammary epithelium created by metastasis. Mammary cancers in mice can be caused by genetic mutations that have been identified in human cancer. This means models can be generated based upon molecular lesions consistent with the human disease.

Cédric Blanpain is a Belgian researcher in the field of stem cells. He is a tenured professor of developmental biology and genetics at Université Libre de Bruxelles and director of the stem cell and cancer lab at its Faculty of Medicine. He was one of the first researchers in the world to use cell lineage tracing in cancer research and he showed for the first time the existence of cancer stem cells in solid tumors in vivo. He was selected by Nature as one of 10 People who mattered most in 2012 and he received the outstanding young investigator award of the International Society for Stem Cell Research.

Axel Behrens is a German-British molecular biologist and an expert in cancer stem cell biology. He is the Scientific Director of the Cancer Research UK Convergence Science Centre in London, a senior group leader at the Institute of Cancer Research and a professor at Imperial College London.

Recurrent cancer is any form of cancer that has returned or recurred when a fraction of primary tumor cells evade the effects of treatment and survive in small spaces that are undetectable by diagnostic tests. The initial tumor may become the site of cancer’s return or it may spread to another part of the body. These surviving cells accumulate various genetic changes over time, eventually producing a new tumor cell. It can take up to weeks, months, or even years for cancer to return. Following surgery and/or chemotherapy or radiotherapy, certain tumor cells may persist and develop resistance to treatment and eventually develop into new tumors. Age, sex, cancer type, treatment duration, stage of advancement, grade of original tumor, and cancer-specific risk factors are some of the factors that determine the rate of cancer recurrence. If recurrent cancer has already moved to other body parts or has developed chemo-resistance then it may be more aggressive than original cancer. In general, the severity of cancer increases with a shorter duration of time between initial treatment and its return.

References

  1. "Professor Jane Visvader" . Retrieved 14 August 2014.
  2. "Structure and function of citrus exocortis viroid / by Jane Ellen Visvader. - Version details - Trove". Trove.nla.gov.au. 28 December 2006. Retrieved 14 August 2014.
  3. "Professor Jane Visvader".
  4. 1 2 3 "News | Royal Society of Victoria | Promoting Science and Science Education". Royalsocietyvictoria.org.au. Retrieved 14 August 2014.
  5. Visvader, Jane E. (2011). "Cells of origin in cancer". Nature. 469 (7330): 314–322. Bibcode:2011Natur.469..314V. doi:10.1038/nature09781. PMID   21248838. S2CID   4418009.
  6. Rios, Anne C.; Fu, Nai Yang; Lindeman, Geoffrey J.; Visvader, Jane E. (2014). "In situ identification of bipotent stem cells in the mammary gland". Nature. 506 (7488): 322–327. Bibcode:2014Natur.506..322R. doi:10.1038/nature12948. PMID   24463516. S2CID   205237171.
  7. Visvader, Jane E.; Lindeman, Geoffrey J. (2012). "Cancer Stem Cells: Current Status and Evolving Complexities". Cell Stem Cell. 10 (6): 717–728. doi: 10.1016/j.stem.2012.05.007 . PMID   22704512.
  8. Giovanni Valenti (11 January 2012). "Interview with Jane Visvader: stem cells in the breast | Europe's stem cell hub". Nature. 439 (7072): 84–88. doi:10.1038/nature04372. PMID   16397499. S2CID   2662840 . Retrieved 14 August 2014.
  9. "Board of Directors - Cancer Council Victoria".
  10. "Patents by Inventor Jane Visvader - Justia Patents Database". Patents.justia.com. Retrieved 14 August 2014.
  11. "GSK Alumni Members" . Retrieved 9 February 2021.
  12. "Fellowship list - Australian Academy of Science". Science.org.au. Retrieved 14 August 2014.
  13. "Top NHMRC research recognised" . Retrieved 9 February 2021.
  14. "THE 2016 LEMBERG MEDAL: JANE VISVADER" . Retrieved 9 February 2021.
  15. "AAHMS announces its second scientific meeting and induction of new fellows" (PDF). Australian Academy of Health and Medical Sciences. Retrieved 14 October 2016.
  16. "Professor Jane Visvader&Professor Geoffrey Lindeman 2017 Victoria Prize for Science & Innovation" . Retrieved 9 February 2021.
  17. "Jane Visvader". Royal Society. Retrieved 20 September 2020.
  18. 1 2 "Prof Jane Visvader".